In individuals with T2DM and NAFLD, the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, like empagliflozin and dapagliflozin, lowers liver fat and raises ALT levels [153,154]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.